Introduction {#S1}
============

Terpenoids, also known as terpenes or isoprenoids, are a large family of natural products. More than 80,000 different terpenoids have been found in almost all life forms. Structural diversity of terpenoids makes them a wide range of applications as pharmaceutical, biofuels, and flavors. The skeletons of terpenoids are derived by condensation of multiple units of isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP), which are naturally generated by either mevalonate (MVA) pathway in eukaryotes and methylerythritol-phosphate (MEP) pathway in prokaryotes and plant plastids. In addition to these natural routes, synthetic routes for non-natural precursors have also been reported ([@B28]; [@B9]; [@B14]). Core structures of terpenes are then post-modified by cytochromes P450s (P450s) that play a vital role in endowing various bioactivities to terpenoids.

Production of terpenoids from natural resources may encounter technical challenges. For instance, ginsenoside Rh2, a potent candidate for cancer therapy, is a triterpenoid saponin derived from *Panax* species ([@B61]). Its content in dried *Panax* ginseng roots is less than 0.01% ([@B57]). Using the synthetic biology approach in engineered yeast, the yield of ginsenoside Rh2 has reached 2.25 g/L in fed-batch fermentation ([@B57]). This result provides an excellent case for improving cell factories to produce plant rare natural products. The rapid advances in synthetic biology suggest an alternative sustainable approach to achieve the industrial scale of terpenoids production ([@B3]; [@B13]; [@B56]). However, several significant challenges remain in microbial biosynthesis as a general approach for the supply of valuable terpenoids, including (i) the biological parts for genetic circuits construction have not been sufficiently characterized; (ii) the post-modifications of terpenoids remains inefficient; and (iii) the toxic accumulation of intermediate products and insufficient supply of precursors. Therefore, a platform that can provide available genetic tools and a comprehensive understanding of its metabolism is urgently needed. In this purpose, *Escherichia coli* and *Saccharomyces cerevisiae* have been used as ideal platform hosts for various creative explorations ([Table 1](#T1){ref-type="table"}). In this review, we focus on recently developed strategies specific to address challenges that in the pathway efficiencies optimization, gene circuits construction and regulation, pathway programing, subcellular engineering and co-culture strategy of terpenoids biosynthesis using synthetic biology approaches.

###### 

Strategies for production of various terpenoids in *S. cerevisiae* and *E. coli*

  Product                Strategy and features                                                                                                                                                                                          Culture conditions         Titer or Improvement   References
  ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------------- ------------
  ***S. cerevisiae***                                                                                                                                                                                                                                                                     
  8-hydroxygeraniol      Mitochondrial compartmentalization by targeting the geraniol biosynthetic pathway to the mitochondria                                                                                                          Fed-batch fermentation     227 mg/L               [@B64]
  Geraniol               Protein structure analysis, site-directed mutation, overexpression of tHMGR and IDI                                                                                                                            Fed-batch fermentation     1.68 g/L               [@B27]
  Limonene               Regulation of ERG20 by P~HXT1~ promoter (glucose-sensitive)                                                                                                                                                    Fed-batch fermentation     917.7 mg/L 6-fold      [@B12]
                         N-degron-mediated destabilization of ERG20                                                                                                                                                                     Batch fermentation         76 mg/L                [@B49]
  Amorpha-4,11-diene     Optimization of \[NADPH\]/\[NADP^+^\] ratios by introducing mutations into phosphofructokinase (PFK) along with overexpression of ZWF1                                                                         Shake flasks               497 mg/L               [@B35]
                         Mitochondria compartmentalization by targeting the whole FPP pathway together with Amorpha-4,11-diene synthase (ADS) into mitochondria                                                                         Shake flasks               427 mg/L               [@B66]
  Zerumbone              Regulation of ERG9 by P~HXT1~ promoter                                                                                                                                                                         Fed-batch fermentation     40 mg/L                [@B68]
  Farnesene              Increase the availability of acetyl-CoA by removing the native source of cytosolic acetyl-CoA (Δ*RHR2*) and overexpressing xPK, PTA, ADA and NADH-HMGr                                                         Fed-batch fermentation     2.24 g/L/h \>130 g/L   [@B44]
  Oxygenated taxanes     *E. coli--S. cerevisiae* co-culture by dividing the synthetic pathway for the acetylated diol paclitaxel precursor into two modules                                                                            Co-culture in bioreactor   33 mg/L                [@B72]
  Nerolidol              Minimizing competition for FPP by destabilizing squalene synthase, degrade ER membrane-integrating protein.                                                                                                    Two-phase flask            4--5.5 g/L             [@B50]
  Casbene                Regulation of ERG20 and ERG9 by P*~HXT1~* and P*~*ERG*1~* promoters                                                                                                                                            Deepwell microplate        108.5 mg/L             [@B5]
  Jolkinol C             Optimize soluble expression of Cbsp using protein tagging strategies, codon-optimization of CYPs                                                                                                               Milliliter plates          800 mg/L               [@B62]
  Carotenoid             Colorimetric-based promoter strength comparison system; inducer/repressor-free sequential control strategy by combining a modified GAL regulation system and a P~HXT1~-controlled squalene synthetic pathway   Fed-batch fermentation     1156 mg/L              [@B63]
  Lycopene               Lipid engineering; Improve triacylglycerol metabolism                                                                                                                                                          Fed-batch fermentation     2.37 g/L               [@B41]
                         Scaffold-free enzyme assemblies (IDI and CrtE);                                                                                                                                                                Fed-batch fermentation     2.3 g/L                [@B30]
  Medicagenic acid       Endoplasmic reticulum (ER) engineering; expand the ER by disrupting the phosphatidic acid phosphatase                                                                                                          Tube cultures              27.1 mg/L 6-fold       [@B2]
  β-Carotene             Tri-functional CRISPR system combines transcriptional activation, transcriptional interference, and gene deletion                                                                                              Tube cultures              2.8-fold               [@B37]
  Squalene               ER engineering; expand the ER by overexpressing a key ER size regulatory factor, INO2.                                                                                                                         Shake flasks               634 mg/L               [@B31]
  ***E. coli***                                                                                                                                                                                                                                                                           
  Total monoterpenoids   Non-natural route to isoprenoid biosynthesis (isoprenoid alcohol pathway/IPA)                                                                                                                                  Shake flasks               0.6 g/L                [@B14]
  Pinene                 Adaptive laboratory evolution for improving pinene tolerance; E. coli co-culture system; whole-cell biocatalysis                                                                                               Shake flasks               166.5 mg/L             [@B47]
                         Cell-free enzyme systems for production of monoterpenes from glucose                                                                                                                                           Glass vials                14.9 g/L               [@B34]
  Limonene               Cell-free enzyme systems                                                                                                                                                                                       Glass vials                12.5 g/L               [@B34]
  Geranyl acetate        Two-phase system; convert monoterpenoid geraniol to its acetyl ester to avoid geraniol toxicity                                                                                                                Fed-batch fermentation     4.8 g/L                [@B8]
  Viridiflorol           Promoters and RBSs engineering                                                                                                                                                                                 Fed-batch fermentation     25.7 g/L               [@B55]
  α-Bisabolol            CRISPRi-guided balancing of MVA pathway                                                                                                                                                                        Shake flasks               25 mg/L                [@B33]
                         FPP-resistant mevalonate kinase 1; lower MVA pathway; Optimization of inducer concentration, aeration and enzymatic cofactor                                                                                   Fed-batch fermentation     8.5 g/L                [@B32]
  Oxygenated taxanes     Modular engineering (MEP, cyclase, and P450 module), promoters engineering                                                                                                                                     Fed-batch fermentation     570 mg/L               [@B4]
  Longifolene            Codon optimization of longifolene synthase, investigate into different FPP synthases                                                                                                                           Fed-batch fermentation     382 mg/L               [@B7]
  Ophiobolin F           Ophiobolin synthase with SUMO tag; phylogenetics based mutation                                                                                                                                                Shake flasks               150.5 mg/L             [@B67]
  Carotenoids            Scaffold-free enzyme assemblies (IDI and CrtE)                                                                                                                                                                 Fed-batch fermentation     276.3 mg/L 5.7-fold    [@B29]
  Astaxanthin            Promoters and RBSs engineering; multidimensional heuristic process (MHP)                                                                                                                                       Fed-batch fermentation     320 mg/L               [@B69]
                         CRISPR-mediated morphology and oxidative stress engineering                                                                                                                                                    Shake flasks               11.92 mg/g DCW         [@B39]
  Zeaxanthin             Dynamic control of MVA pathway by IPP/FPP-responsive promoter.                                                                                                                                                 Fed-batch fermentation     722.46 mg/L            [@B54]
  Lycopene               CRISPRi-guided balancing of MVA pathway                                                                                                                                                                        Shake flasks               71.4 mg/L              [@B33]
                         Optimization of the lycopene biosynthetic; Overexpressing the MEP pathway                                                                                                                                      Shake flasks               448 mg/g DCW           [@B15]

Genetic Circuits and Dynamic Control {#S2}
====================================

As the basic genetic elements of biosynthetic pathways, biological parts (e.g., promoter, terminator, ribosome-binding site (RBS), regulatory protein, etc.) should be well-characterized and optimized for synthetic biology. Constitutive or inducible promoters with different strengths are always the major theme in synthetic biology. Their efficiency are also affected by the combination of terminators and RBS.

Comparing to constitutive promoters, inducible promoters possess a strong capacity to start gene expression only under specific culture conditions. For example, the glucose-sensing promoter *HXT1*(P*~*HXT*1~*) is strong at high glucose concentrations and weak at low glucose concentrations. Using glucose-responsive promoters also avoids the need for expensive repressors or inducers ([@B53]; [@B63]; [@B71]; [@B12]). By using P*~*HXT*1~*, the competing gene farnesyl diphosphate synthase (ERG20) for the consumption of precursors IPP and DMAPP was inhibited, and the carbon flux was reallocated from the growth pathway to the limonene synthetic pathway, and the limonene titer reached 917.7 mg/L in fed-batch fermentation ([@B12]). When each of MVA pathway enzymes was transcribed from high-expression galactose-regulated promoters (*P~*GAL*1~* or *P~*GAL*10~*), an amorpha-4,11-diene yield of more than 40 g/L was resulted ([@B60]). FPP (farnesyl diphosphate) is the intermediate of MVA pathway, but exhibits toxicity when it accumulates in *E. coli* ([@B42]). Whole-genome transcript arrays identified an FPP-responsive promoter answering to the accumulation of FPP ([@B16]). Using IPP/FPP-responsive promoter in *E. coli*, [@B54] coordinated the expression of all genes of the MVA pathway from *S. cerevisiae* using the tunable intergenic regions to increase the availability of FPP. The dynamically regulated MVA pathway prevented the toxic accumulation of IPP/FPP, and the titer of zeaxanthin reached 722.46 mg/L in fed-batch fermentation ([Supplementary Figure S1A](#FS1){ref-type="supplementary-material"}). P*~*ERG*1~* represents an ergosterol-sensitive promoter, was shown to restrict squalene synthase (ERG9) expression levels efficiently ([@B65]). [@B5] replaced the promoter regions of *ERG20* and *ERG9* with P*~*HXT*1~* and P*~*ERG*1~* to redirect the flux from FPP and sterols, generated a titer of 108.5 mg/L of casbene.

Clustered regularly interspaced short palindromic repeats interference (CRISPRi) uses a catalytically-inactive Cas9 protein (dCas9) and a single guide RNA (gRNA) to repress the expression of targeted genes by blocking transcription ([@B52]). [@B33] established a dynamic regulation CRISPRi system to coordinate the metabolic flux between cell growth and IPP/DMAPP accumulation. An L-rhamnose-inducible promoter was used to control the expression of dCas9. During the production phase, L-rhamnose was removed to restore gene expression, and the production of lycopene and α-bisabolol increased. [@B37] developed a CRISPR-AID system using three orthogonal CRISPR proteins combines. When *HMG1* was overexpressed, down-regulation of *ERG9* and deletion of *ROX1* could significantly increase the production of β-carotene in *S. cerevisiae*. These genes were chosen as the targets for CRISPRa (transcriptional activation), CRISPRi, and CRISPRd (gene deletion), respectively ([Supplementary Figure S1B](#FS1){ref-type="supplementary-material"}).

The modular pathway engineering group multiple genes into modules to reduce regulatory complexities and help to unlock the potential of the multi-gene pathway for the production of terpenoid products ([@B1]; [Supplementary Figure S1C](#FS1){ref-type="supplementary-material"}). Keasling's group tuned the expression of multiple genes within operons by generating libraries of tunable intergenic regions and balancing the expression of MVA pathway, which resulted in a 7-fold increase in mevalonate production ([@B51]). [@B69] reported a multidimensional heuristic process for astaxanthin production. Astaxanthin biosynthesis pathway was grouped into four modules, that each module controlled by different promoter of pre-determined strength, and get a yield of 320 mg/L in *E. coli*. Through screening of combinations of promoters and terminators, valencene synthase expression cassette was optimized to reach a titer of 539.3 mg/L ([@B10]). When [@B55] introduced viridiflorol synthase (VS) from *Agrocybe aegerita* to *E. coli*, three T7 promoter variants were characterized for different pathway expression, and RBS libraries that covered a broad range of translational initiation rates were optimized. The yield of viridiflorol was increased to 25.7 g/L in fed-batch fermentation.

Pathway Enzyme Design {#S3}
=====================

Directed evolution and rational protein design have been used to engineer enzymes in heterologous pathways ([@B19]; [@B47]; [@B24]; [Supplementary Figure S1E](#FS1){ref-type="supplementary-material"}). Monoterpenes are synthesized from geranyl diphosphate (GPP), which is also the precursor for the biosynthesis of FPP. Therefore, preventing the consumption of GPP by restricting FPP formation is profitable to produce monoterpenes. [@B45] introduced a mutation (Ser81 to Phe) in native FPP synthase of *E. coli*, resulting in an enzyme that preferentially synthesizes GPP instead of FPP, and the engineered strains yielded 653 mg/L of 1,8-cineole and 505 mg/L of linalool, which are 30- and 5-fold improvement, respectively. [@B27] demonstrated that two essential amino acid residues Y436 and D501 located in active pocket of the key enzyme geraniol synthase are critical for the key step of dephosphorylation. By overexpression of truncated 3-hydroxy-3-methylglutaryl-coenzyme reductase (tHMGR) and isopentenyl diphosphate isomerase (IDI), the highest titer of 1.68 g/L geraniol was achieved in fed-batch fermentation in *S. cerevisiae.*

Protein tagging strategies are effective means for enzyme engineering. A truncated gene encoding casebene synthase from *Jatropha curcas* with various protein tags was integrated into a geranylgeranyl diphosphate (GGPP)-producing strain, which yields 160 mg/L of casbene ([@B62]). Using a small ubiquitin-like modifier (SUMO) fusion tag and phylogenetics based mutations, ophiobolin synthase solubility and activity were improved. The yield of sesterterpene ophiobolin F was increased to 150.51 mg/L in *E. coli* ([@B67]). Endoplasmic reticulum-associated protein degradation decreased cellular levels of ERG9, and increased the titer of sesquiterpene nerolidol to 100 mg/L ([@B50]). Also, N-degron-mediated destabilization of ERG20 improved the production of monoterpenes of 18 mg/L linalool or 76 mg/L limonene in *S. cerevisiae* ([@B49]). To decrease the concentration of pivotal enzyme, a synthetic degradation has been established based on *Mesoplasma florum* tmRNA system ([@B6]). Based on the CRISPRi and the N-end rule for protein stability, [@B43] described a genome editing approach by changing the rates of both RNA synthesis and protein degradation. Synthetic protein scaffolds provide precise control of metabolic flux by preventing the loss of intermediates to diffusion or competing pathways ([@B18]). However, scaffolded enzyme assemblies have different limitations, as enzymes fused in large structures may encounter a decrease or complete loss of the activity ([@B26]). Recently, [@B30] developed a scaffold-free modular enzyme assembly by employing a pair of short peptide tags. The GGPP synthase and IDI were modularly assembled, which increased carotenoid production by 5.7-folds in *E. coli* and yielded a titer of 2.3 g/L lycopene in *S. cerevisiae*.

Reprograming and Design New Precursor Biosynthetic Pathways {#S4}
===========================================================

High intracellular levels of the essential intermediate IPP, may cause growth inhibition, reduce cell viability and plasmid instability ([@B42]; [@B20], [@B21]). To explore more efficient and practical terpenoids biosynthetic pathways, non-natural pathways were developed. Kang et al. reported an alternative IPP-bypass MVA pathway by utilizing promiscuous activities of phosphomevalonate decarboxylase and an *E. coli* endogenous phosphatase, which successfully decoupled isopentenol production from IPP generation, and remarkably improved isoprenol titer to 3.7 g/L in batch cultures ([@B28]; [@B29]). [@B14] constructed an isoprenoid alcohol pathway (IPA) for terpenoids synthesis, which could convert isoprenoid precursors through a minimal number of steps, and less ATP consumption. [@B9] established an isopentenol utilization pathway (IUP) for bioconversion of isopentenols, isoprenol, or prenol to IPP or DMAPP. The IUP is composed of choline kinase (from *S. cerevisiae*), isopentenyl phosphate kinase, and isopentenyl-pyrophosphate delta isomerase and requires ATP as its sole co-factor, whereas much more straightforward than the current MVA or MEP alternatives.

Acetyl-CoA is also the critical branch-point precursor for terpenoids biosynthesis. However, in *S. cerevisiae*, acetyl-CoA is compartmentalized that mainly derived from pyruvate in mitochondria and fatty acids degradation in the peroxisome ([@B23]). [@B44] rewired the central carbon metabolism of *S. cerevisiae* to improve redox balance and enable biosynthesis of cytosolic acetyl-CoA with a reduced ATP requirement. The engineered strains produced 25% more farnesene while requiring 75% less oxygen, and sustaining stable yield for 2 weeks that reaches \>130 g/L farnesene. This system has provided a reference for all terpenoids and other acetyl-CoA-derived compounds. [@B40] constructed a synthetic acetyl-CoA pathway, in which, the catalytic activity of glycolaldehyde synthase was improved by directed evolution. Then the acetyl-phosphate synthase was selected based on the phylogenetic tree of PKs, which converts glycolaldehyde into acetyl-phosphate (AcP). AcP could be used to generate acetyl-CoA by the phosphate acetyltransferase. It is the shortest pathway from formaldehyde to acetyl-CoA.

In *S. cerevisiae*, NADPH production highly depends on the oxidative pentose phosphate pathway ([@B46]). [@B35] engineered mutated phosphofructokinase (PFK) along with overexpression of glucose-6-phosphate dehydrogenase to reduce glycolytic metabolic fluxes, resulted in substantial increases of \[NADPH\]/\[NADP^+^\] ratios. Moreover, amorpha-4,11-diene was overproduced in *S. cerevisiae* achieved a titer of 497 mg/L with a 3.7-fold increase compared to the parental strain.

Subcellular Engineering and Cell Free System {#S5}
============================================

Compared with cytosol, mitochondria provide a compartmentalized environment with higher reducing redox potential. There is a growing interest in utilizing the acetyl-CoA pool in mitochondria for the biosynthesis of value-added compounds. By transplanting the whole FPP pathway together with amorpha-4,11-diene synthase into yeast mitochondria, the yield of amorpha-4,11-diene in engineered strain reached 427 mg/L ([@B66]). [@B64] targeted the geraniol biosynthetic pathway to the *S. cerevisiae* mitochondria to protect the GPP pool from consumption by the cytosolic ergosterol pathway. The production of geraniol in mitochondrial was 6-fold increase compared to cytosolic producing strains ([Figure 1A](#F1){ref-type="fig"}). Lipid droplets (LDs) are ubiquitous organelles that store metabolic energy in the form of neutral lipids. [@B41] established a lipophilic lycopene production strategy in *S. cerevisiae* by using LDs accumulation. A non-oleaginous *S. cerevisiae* for triacylglycerols production was combined with their composition adjustment and LDs size regulation. Therefore, lycopene accumulated continuously to 2.37 g/L in 5 days ([Figure 1B](#F1){ref-type="fig"}). Expansion of the endoplasmic reticulum (ER) could increase yeast metabolic capacity. [@B2] reported that the disruption of the phosphatidic acid phosphatase (PAH) resulted in the expansion of the ER, which stimulated the production of triterpene biosynthesis enzymes and increased triterpenoid and triterpene saponin accumulation. [@B31] engineered *S. cerevisiae* to expand the ER by overexpressing a key ER size regulatory factor, INO2. The production of squalene was increased by 71-fold, with the titer of 634 mg/L in shake flask fermentation ([Figure 1C](#F1){ref-type="fig"}). [@B38] compartmentalized yeast peroxisome as a subcellular factory for squalene biosynthesis. Hybridization of the cytoplasm- and peroxisome-engineered strains was constructed, and squalene with a titer of 11.0 g/L was reached in two-stage fed-batch fermentation ([Figure 1D](#F1){ref-type="fig"}).

![Overview of terpenoids biosynthesis by subcellular engineering **(A--D)**, and cell-free terpenoids biosynthesis **(E)**. Yeast cells contain various subcellular organelles (e.g., mitochondria, endoplasmic reticulum, etc.) which provide beneficial circumstances for different terpenoids biosynthetic pathways. Cell-free biosynthesis systems by *in vitro* reconstructing the entire biosynthetic pathway is another efficient solution for terpenoid production. PDH, pyruvate dehydrogenase; IDI, isopentenyl diphosphate isomerase; FPS, farnesyl diphosphate synthase; GES, geraniol synthase; PAH, phosphatidic acid phosphatase; ACS, acetyl-CoA synthetase; ACL, ATP-dependent citrate lyase; ERG20, farnesyl diphosphate synthase; ERG9, squalene synthase; NADH-HMGR, NADH-specific HMG-CoA reductase.](fbioe-08-00347-g001){#F1}

On the other hand, cell free biosynthesis (CFB) systems are easy to use multiple enzyme pathways sourced from various organisms, and also overcome the challenges of precursor supply and products toxicity. The purified enzyme system and crude cell extract system are common application forms of CFB systems ([@B17]; [@B36]; [Figure 1E](#F1){ref-type="fig"}). CFB systems designed by [@B34] converted glucose into monoterpenes and can be self-sustaining for long periods. The platform contains 27 enzymes and using glycolysis reconstituted to generates both ATP, NADPH, and acetyl-CoA, resulting in the production of 12.5 g/L limonene and 14.9 g/L pinene. In addition, CFB systems provide great flexibility for biochemical pathways study. [@B11] utilized *in vitro* metabolic engineering to reveal the regulatory network of a reconstituted amorpha-4,11-diene synthetic pathway, and identified the inhibition of ATP on both FPP synthase and amorpha-4,11-diene synthase.

Cytochromes P450 and Post-Modifications of Terpenoids {#S6}
=====================================================

Cytochromes P450 (P450s) play a crucial role in yielding final terpenoid products with wide chemical diversity and bioactivities. *S. cerevisiae* is a favored host for expressing P450s on account of advanced protein expression mechanism, abundant intracellular membranes and the inherent benefits of large-scale microbial fermentation ([@B48]; [@B22]; [@B62]; [@B68]). It is generally deemed that the ability to express soluble P450s in *E. coli* is limited. The main challenge is the lack of an endomembrane system for attachment of the eukaryotic P450s, as they have a helical hydrophobic transmembrane domain containing 20--30 amino acid residues at their N-terminal ends. Transmembrane domain truncation and N-terminal replacement are vastly used for heterologous expression of eukaryotic P450s. [@B25] performed extensive heterologous expression of fungal P450s in *E. coli* using 304 of P450 isoforms and identified N-terminal amino acid sequences that can significantly improve chimeric P450s expression levels. They revealed that the choice of combinations of N-terminal and catalytic domains is critical for high-level expression. [@B4] demonstrated *E. coli* could be a feasible host for P450-mediated terpenoid biosynthesis. In their study, the first module, "MEP," was comprised of the rate-limiting enzymes of the IPP-producing MEP pathway. The second "cyclase" module was comprised of taxadiene synthase (TxS) and GGPP synthase. The relatively low expression of a five-copy plasmid with a weak promoter was essential for P450 and CPR functionality. Besides, with reductase partner interactions and N-terminal modifications, a record yield of 570 mg/L of oxygenated taxanes was achieved in *E. coli*.

The important post-modifications of terpenoids also include hydroxylation by P450s and glycosylation by glycosyltransferases. [@B22] showed a platform for the production of steviol glucosides (SGs) in *S. cerevisiae*. Two P450s of kaurene oxidase (KO) and kaurenoic acid hydroxylase (KAH) are required in succession in the conversion of kaurene into steviol. By optimizing the copy number modulation of KO-KAH-CPR combinations, the conversion was maximized. [@B58], [@B57] established a series of cell factories to produce ginsenoside Rh2 by optimizing UDP-glycosyltransferase bioparts expression. Combined with precursor (protopanaxadiol) supply optimization, the titer of ginsenoside Rh2 reached 2.25 g/L in fed-batch fermentation.

Co-Culture of Engineered Strains {#S7}
================================

A newly approach of co-culture engineering to enhance terpenoids production was developed. In some conditions, a single host cell cannot provide an optimal environment for functioning all pathway enzymes, and metabolic burdens from overexpression of complex pathways may reduce biosynthetic efficiency ([@B70]; [@B59]). By dividing the acetylated diol paclitaxel precursor synthetic route into two modules, expressed in either *S. cerevisiae* or *E. coli*, a stable co-culture was achieved in the bioreactor. The engineered *E. coli* strain accomplishes the biosynthesis of the intermediate taxadiene. Meanwhile, *S. cerevisiae* is the preferred host for cytochrome P450 (P450s) expression, using this two-component system, oxygenated taxanes with a titer of 33 mg/L was overproduced ([@B72]; [Supplementary Figure 1D](#FS1){ref-type="supplementary-material"}). Similarly, [@B47] constructed an *E. coli* - *E. coli* co-culture system for pinene biosynthesis. The MEV pathway and heterologous pathway (the GPP synthase and pinene synthase) were engineered in different pinene tolerance *E. coli* strains, respectively. The optimization of whole-cell biocatalysis, which could separate cell growth and production phase, improved pinene production to 166.5 mg/L.

Conclusion {#S8}
==========

Over the last few decades, biological engineers achieved grand developments in synthetic biology. The enormous potential of *E. coli* and *S. cerevisiae* as platform strains has been confirmed with various successes. However, as synthetic biology targets are progressively more complicated, there remain some challenges to engineering industrial hosts because of the lack of knowledge of complex biochemical and cellular metabolism and its regulation. With the fast development of synthetic biology tools such as CRISPR-Cas9, adaptive laboratory evolution (ALE) combine with next-generation sequencing and high-throughput screening, it promises to reach a deeper understanding of cellular metabolism. The capacity of DNA synthesis has been made great progressed over the past decade, and it is conventional to synthesize the large gene cluster for terpenoids biosynthesis. In addition, new DNA assembly methods facilitate the speedy construction of different genetic part combinations or to replace genetic parts in a single step. Besides, dynamic control, compartmentalization, module design, or cell-free system are practical methods to enhance the overall reaction efficiency of multi-enzyme pathways.
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